1Y Close · As of Aug 26, 2026
HLB Life Science operates in the Pharmaceuticals sector.
Legal name: HLB Life Science CO.,LTD.
In fiscal year 2025, HLB Life Science (067630) reported revenue of 45.8 billion KRW, down 55.3% from 102.2 billion KRW a year earlier.
Operating profit was -22.0 billion KRW and net income was -99.9 billion KRW in the same year.
As of the Aug 26, 2026 close, the market capitalization was 334.7 billion KRW, with a P/B of 1.12.
These figures can be verified in the DART filing (receipt no. 20260323001728).
Financials
| Year | Rev | Op Inc | Net Inc |
|---|---|---|---|
| 2025 | 45.8B | -22.0B | -99.9B |
| 2024 | 102.2B | -24.8B | 6.2B |
| 2023 | 98.0B | -24.5B | -5.9B |
Recent Filings
Disposal of Other Shares
교환가액의조정 (제16회차)
전환사채(해외전환사채포함)발행후만기전사채취득 (제13회차)
Checks
3 of 8 checked items currently applicable.
Market Cap & Price: Market cap is above the delisting threshold.
Audit Opinion: Audit opinion: Unqualified (clean).
Capital Increase: No capital-increase filings in the last 180 days.
Treasury Stock: No treasury stock filings.
Embezzlement & Litigation: No embezzlement or litigation filings in the last 180 days.
Major Shareholder Change: No major shareholder changes in the last 180 days.
Recent Filings
| Date | Filing |
|---|---|
| 2026-08-26 | Disposal of Other Shares |
| 2026-08-20 | 교환가액의조정 (제16회차) |
| 2026-08-14 | 전환사채(해외전환사채포함)발행후만기전사채취득 (제13회차) |
| 2026-08-13 | Semi-Annual Report (2026.06) |